Skeletal Muscle Atrophy and Dysfunction in Human Cancer
NCT ID: NCT02949076
Last Updated: 2023-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
11 participants
INTERVENTIONAL
2016-07-31
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise
Lung cancer patients will undergo unilateral resistance exercise 3 times per week for 8 weeks during cancer treatment, while the other leg remains unexercised and will serve as a within-subject control.
Exercise
Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* histologically-documented, stage III or IV non-small cell lung carcinoma (NSCLC)
* estimated life expectancy \>6 mos
* Karnofsky's performance score of ≥70
Exclusion Criteria
* uncontrolled hypertension
* heart or renal failure
* exercise limitations from peripheral vascular disease or stroke
* neuromuscular disease
* knee/hip replacement
* additional, actively-treated malignancy or history of malignancy, except non-melanoma skin cancer
* taking medication that can have anti-coagulant effects that cannot be stopped prior to the muscle biopsy
50 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of South Carolina
OTHER
University of Vermont
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael J. Toth, Ph.D.
Associate Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael J. Toth, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Vermont
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Vermont College of Medicine
Burlington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-506
Identifier Type: -
Identifier Source: org_study_id